Matches in SemOpenAlex for { <https://semopenalex.org/work/W3031103612> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W3031103612 abstract "e16524 Background: Keynote-181 study reported anti-PD-1 antibody pembrolizumab as monotherapy had shown superior efficacy compared to CT for previously treated patients (pts) with advanced ESCC. The combination of anti-PD-1 antibody and CT may be a feasible approach to provide antitumor activity superior to either agent alone. However, the available data about the combination strategy is limited. Methods: We retrospectively reviewed the records of pts treated at our center to identify pts seen between 7/2019 and 12/2019 with recurrent or metastatic ESCC who received treatment with Camre (anti-PD-1 antibody) plus taxane-based CT. The primary endpoints were objective response rate (ORR) and disease control rate (DCR) per RECIST 1.1. Secondary endpoint included toxicity. The carcinoembryonic-antigen (CEA) dynamics and clinical associations were also evaluated in the selected pts. Results: A total of 14 pts were identified. The median age was 66 years (44-80). Most pts were male (12/14, 85.7%) with metastatic disease (10/14, 71.4%). The CT regimens contained nab-paclitaxel in 4 pts, nab-paclitaxel plus nedaplatin in 2, liposomal paclitaxel in 2, liposomal paclitaxel plus nedaplatin in 6. Camre in combination with CT were repeated every 3 to 4 weeks for up to 4 cycles. Two pts also received maintenance therapy of Camre for 4 and 6 cycles. Five pts (35.7%) exhibited a best overall response of PR, 6 (42.9%) SD, and 3 (21.4%) PD. The ORR and DCR were 35.7% (5/14) and 78.6% (11/14), respectively. All the SD determination as the best response met the minimum interval of 8 weeks from baseline. Toxicity profile was mild with mainly grade 1, expected toxicities. The most common grade 3/4 adverse events were leucopenia (2/14, 14.3%) and neutropenia (2/14, 14.3%). CEA baseline levels were normal in 6 cases, elevated in 8. It was observed that CEA levels closely paralleled overall measurable tumor burdens in all the CEA-elevated pts. A patient with equivocal radiographic pseudoprogression even had CEA dynamics that correlated with eventual clinical outcome. Conclusions: We identified a group of pts of recurrent or metastatic ESCC treated with Camre plus taxane-based CT and achieving a favorable DCR to therapy with a tolerable toxicity profile. This combination regimen warrants further exploration in a prospective clinical trial. CEA dynamics may be a useful tool to monitor disease evolution in this setting." @default.
- W3031103612 created "2020-06-05" @default.
- W3031103612 creator A5005724266 @default.
- W3031103612 creator A5020943526 @default.
- W3031103612 creator A5029755293 @default.
- W3031103612 creator A5047585931 @default.
- W3031103612 creator A5050895396 @default.
- W3031103612 creator A5064069337 @default.
- W3031103612 creator A5070654335 @default.
- W3031103612 date "2020-05-20" @default.
- W3031103612 modified "2023-09-27" @default.
- W3031103612 title "Camrelizumab (Camre) plus taxane-based chemotherapy (CT): Clinical outcomes and dynamic monitoring of CEA as a predictive biomarker of response in patients with recurrent or advanced esophageal squamous cell carcinoma (ESCC)." @default.
- W3031103612 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.e16524" @default.
- W3031103612 hasPublicationYear "2020" @default.
- W3031103612 type Work @default.
- W3031103612 sameAs 3031103612 @default.
- W3031103612 citedByCount "0" @default.
- W3031103612 crossrefType "journal-article" @default.
- W3031103612 hasAuthorship W3031103612A5005724266 @default.
- W3031103612 hasAuthorship W3031103612A5020943526 @default.
- W3031103612 hasAuthorship W3031103612A5029755293 @default.
- W3031103612 hasAuthorship W3031103612A5047585931 @default.
- W3031103612 hasAuthorship W3031103612A5050895396 @default.
- W3031103612 hasAuthorship W3031103612A5064069337 @default.
- W3031103612 hasAuthorship W3031103612A5070654335 @default.
- W3031103612 hasConcept C121608353 @default.
- W3031103612 hasConcept C126322002 @default.
- W3031103612 hasConcept C141071460 @default.
- W3031103612 hasConcept C143998085 @default.
- W3031103612 hasConcept C203092338 @default.
- W3031103612 hasConcept C2776694085 @default.
- W3031103612 hasConcept C2777292972 @default.
- W3031103612 hasConcept C2777511904 @default.
- W3031103612 hasConcept C2778203143 @default.
- W3031103612 hasConcept C2778239845 @default.
- W3031103612 hasConcept C2778822529 @default.
- W3031103612 hasConcept C2779984678 @default.
- W3031103612 hasConcept C530470458 @default.
- W3031103612 hasConcept C535046627 @default.
- W3031103612 hasConcept C71924100 @default.
- W3031103612 hasConcept C90924648 @default.
- W3031103612 hasConceptScore W3031103612C121608353 @default.
- W3031103612 hasConceptScore W3031103612C126322002 @default.
- W3031103612 hasConceptScore W3031103612C141071460 @default.
- W3031103612 hasConceptScore W3031103612C143998085 @default.
- W3031103612 hasConceptScore W3031103612C203092338 @default.
- W3031103612 hasConceptScore W3031103612C2776694085 @default.
- W3031103612 hasConceptScore W3031103612C2777292972 @default.
- W3031103612 hasConceptScore W3031103612C2777511904 @default.
- W3031103612 hasConceptScore W3031103612C2778203143 @default.
- W3031103612 hasConceptScore W3031103612C2778239845 @default.
- W3031103612 hasConceptScore W3031103612C2778822529 @default.
- W3031103612 hasConceptScore W3031103612C2779984678 @default.
- W3031103612 hasConceptScore W3031103612C530470458 @default.
- W3031103612 hasConceptScore W3031103612C535046627 @default.
- W3031103612 hasConceptScore W3031103612C71924100 @default.
- W3031103612 hasConceptScore W3031103612C90924648 @default.
- W3031103612 hasLocation W30311036121 @default.
- W3031103612 hasOpenAccess W3031103612 @default.
- W3031103612 hasPrimaryLocation W30311036121 @default.
- W3031103612 hasRelatedWork W11093380 @default.
- W3031103612 hasRelatedWork W11779430 @default.
- W3031103612 hasRelatedWork W13328401 @default.
- W3031103612 hasRelatedWork W1743485 @default.
- W3031103612 hasRelatedWork W18425634 @default.
- W3031103612 hasRelatedWork W1852032 @default.
- W3031103612 hasRelatedWork W19355547 @default.
- W3031103612 hasRelatedWork W2544042 @default.
- W3031103612 hasRelatedWork W5038423 @default.
- W3031103612 hasRelatedWork W8188359 @default.
- W3031103612 isParatext "false" @default.
- W3031103612 isRetracted "false" @default.
- W3031103612 magId "3031103612" @default.
- W3031103612 workType "article" @default.